Boehringer Ingelheim, OSE Launch Up-to-$1.4B+ Immuno-Oncology Partnership

Boehringer Ingelheim has committed a potential $1.4 billion-plus toward cancer immunotherapy by partnering with OSE Immunotherapeutics to develop its late preclinical candidate OSE-172 (Effi-DEM), a novel checkpoint inhibitor antibody designed to treat solid tumors.Boehringer and OSE have entered into a global license and collaboration agreement to develop OSE-172, an anti-Signal Regulatory Protein Alpha (SIRP-alpha) monoclonal antibody that targets myeloid lineage cells, including dendritic cel